Investigadores del Cima han identificado un gen que está implicado en el desarrollo del cáncer de pulmón y de páncreas. Se trata de un transportador de fosfolípidos (proteínas de las membranas c...
KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human tumours. The dev...
Researchers from the Experimental Oncology Group at the CNIO have achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that a...
The specific combination of the drugs dasatinib and demcizumab impairs the growth of KRAS-driven lung tumours, the most aggressive sub-type and with the lowest survival rates